文献速递慢性肾脏病遗传性与小管间质肾病肾血管病与高血压

骨质疏松与CKD-MBD同属一个框架:联合科学研讨会的见解

Osteoporosis and CKD-Metabolic Bone Disease Under the Same Umbrella: Insights From a Joint Scientific Symposium.
PubMed 文献 · Kidney Int Rep · 2026-02-17

骨质疏松与慢性肾脏病-代谢性骨病(CKD-MBD)日益被视为重叠疾病,尤其在老龄人群中。肾功能下降与骨骼脆性常共存,CKD-MBD可在已有骨质疏松的骨骼上发生。无动力骨病常因PTH过度抑制所致,组织学上可类似低转换型骨质疏松,光镜下难以区分,可靠鉴别常依赖临床背景。肾内科与非肾内科骨专科医生常平行而非协作工作,导致诊断缺口和管理碎片化。影像学、生化标志物和骨组织形态计量学进展增进了对疾病机制的理解,但当前诊断方法仍有局限。骨质疏松治疗在CKD中常未被充分利用,尽管越来越多证据支持在更广肾功能范围内有效安全。血管钙化由钙磷稳态紊乱驱动,与CKD心血管发病和死亡强相关,但在临床决策中优先级不足。间歇性PTH给药等新概念可能恢复矿物质平衡和改善骨骼完整性,能否影响心血管风险尚不确定,值得研究。

要点

  • CKD-MBD与骨质疏松常重叠,无动力骨病与低转换型骨质疏松光镜下难区分。
  • 肾内科与骨专科医生协作不足,导致诊断缺口和管理碎片化。
  • 骨质疏松治疗在CKD中常未被充分利用,血管钙化优先级不足。

核心结论

  • 骨质疏松与CKD-MBD日益被视为重叠疾病,尤其在老龄人群中。
  • 肾内科与非肾内科骨专科医生常平行而非协作,导致诊断缺口和管理碎片化。
  • 骨质疏松治疗在CKD中常未被充分利用,血管钙化在临床决策中优先级不足。

研究设计与样本

  • 本文为联合科学研讨会的见解总结(综述类)。

主要发现

  • 肾功能下降与骨骼脆性常共存,CKD-MBD可在已有骨质疏松的骨骼上发生。
  • 无动力骨病常因PTH过度抑制所致,组织学上可类似低转换型骨质疏松,光镜下难以区分。
  • 影像学、生化标志物和骨组织形态计量学进展增进了对疾病机制的理解,但当前诊断方法仍有局限。
  • 骨质疏松治疗在CKD中常未被充分利用,尽管越来越多证据支持在更广肾功能范围内有效安全。
  • 血管钙化由钙磷稳态紊乱驱动,与CKD心血管发病和死亡强相关,但临床决策中优先级不足。

关键数值与推荐

  • 无动力骨病常因PTH过度抑制所致,组织学上可类似低转换型骨质疏松。
  • 骨质疏松治疗在CKD中常未被充分利用,尽管证据支持在更广肾功能范围内有效安全。
  • 血管钙化与CKD心血管发病和死亡强相关。

临床怎么用

  • 肾内科与骨专科医生应协作管理CKD患者的骨质疏松与CKD-MBD。
  • 对CKD患者应评估骨质疏松治疗的应用,避免因肾功能而低估其获益。
  • 临床决策中应重视血管钙化的评估与管理。

局限性

  • 当前诊断方法仍有局限,无动力骨病与低转换型骨质疏松光镜下难以区分。
  • 骨质疏松定义超越BMD后临床误分类仍持续。
  • 间歇性PTH给药能否影响心血管风险尚不确定,值得研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Osteoporosis and chronic kidney disease (CKD)-metabolic bone disease (MBD) (CKD-MBD) are increasingly recognized as overlapping conditions, particularly in the aging population. Declining renal function and skeletal fragility often coexist, because CKD-MBD may develop in a skeleton already compromised by preexisting osteoporosis. Adynamic bone, often resulting from excessive suppression of parathyroid hormone (PTH) and now a common form of renal osteodystrophy (ROD), may histologically resemble low-turnover osteoporosis; distinguishing between the 2 under light microscopy remains difficult, and reliable differentiation often depends on clinical context. Nevertheless, nephrologists and nonnephrologist bone specialists frequently work in parallel rather than in collaboration.This separation has contributed to persistent diagnostic gaps and fragmented management, especially in patients with advanced CKD. Advances in imaging, biochemical markers, and bone histomorphometry have improved insight into disease mechanisms; however, limitations in current diagnostic approaches remain. Osteoporosis therapies are frequently underused in CKD, despite growing evidence supporting efficacy and safety across a broader range of kidney function than previously assumed. Despite efforts to refine the definition of osteoporosis beyond bone mineral density (BMD) alone, clinical misclassification continues.Beyond skeletal health, vascular calcification (VC)-driven by disordered calcium-phosphate homeostasis-remains insufficiently prioritized in clinical decision-making, despite its strong association with cardiovascular morbidity and mortality in CKD. Emerging concepts, such as intermittent PTH administration, an established treatment in osteoporosis, illustrate the potential for interventions that may restore mineral balance and improve skeletal integrity in selected CKD populations. Whether such strategies can also favorably influence cardiovascular risk remains uncertain and warrant investigation. This integrated framework may improve interdisciplinary care.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Dempster DW, Evenepoel P, Nickolas TL, et al. Osteoporosis and CKD-Metabolic Bone Disease Under the Same Umbrella: Insights From a Joint Scientific Symposium. Kidney Int Rep. 2026. PMID: 41852575. doi:10.1016/j.ekir.2026.106362

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。